CROMA-PHARMA/CNBG
15.9.2020 15:02:14 CEST | Business Wire | Press release
Asia in general and China in particular represent the fastest growing aesthetic medicine markets worldwide. CNBG and Croma entered a far reaching, long-term cooperation combining each partner’s assets in a newly founded Joint Venture company to market Croma’s aesthetic products in China and Hong Kong. Financial details were not disclosed by the parties.
The cooperation between CNBG and Croma will in all probability have a major impact on the aesthetic medicine market in China, which had seen an average growth of over 20% annually within the past years. This caused an increasing demand for safe, high-quality products.
Croma will contribute its products, the currently approved Hyaluronic Acid Filler Princess® VOLUME and additional Filler products, as well as other facial aesthetic products of its range, whereas CNBG will provide its multi-channel distribution, marketing knowledge and synergistic products, in particular its botulinum toxin product Heng Li® , manufactured by the CNBG affiliate Lanzhou Biotechnique Development Co., Ltd. (“Lanzhou”).
The joint company aims to become a comprehensive supplier of minimally invasive aesthetic products in China, making effective use of the existing field force of Lanzhou. Sales of Princess® VOLUME will re-start very soon.
Xiangrong Li, Vice-president of CNBG said: “CNBG, via its affiliate Lanzhou, has been very successful for years with its botulinum toxin in China. Our search for suitable HA Filler products has finally come to an end – Croma indeed is the perfect partner and best possible fit for us. Together we are committed to shape and conquer the Chinese market with all its immense growth potential”.
Andreas Prinz, CCO and Co-Owner of Croma: "Croma incorporates more than 40 years of experience in R&D of viscoelastic products. Our fully automated production lines deliver 8 million pre-filled injectables per year. We are rightfully considered leading European experts in Hyaluronic Acid. With CNBG, we have found the perfect partner to merge our strengths and assets to successfully enter the fast-growing Chinese market. CNBG’s track-record and experience will heavily support Croma to sustainably prosper in Asia ."
About Croma-Pharma GmbH - leading experts in Hyaluronic Acid
Croma-Pharma, a family owned pharmaceutical company based in Austria is globally acclaimed for its expertise in pre-filled viscoelastic injectables for opthalmology, orthopaedics and aesthetic indications. Annual output of 8 million syringes makes Croma one of the major producers of high-end injectables worldwide. The success is based on research and development at the company headquarters in Austria. The owners follow a clear vision for high-quality technologies and boldly seize opportunities for the acquisition of complementary companies or technologies. Croma currently employs around 500 people and operates 12 affiliates in Europe, North-America, Brazil and Australia. Through distribution partnerships, its products are marketed in more than 70 countries all over the world. Croma is a multi-award winning company and celebrated its 40th anniversary in 2016.
About CNBG
CNBG is one of the largest Chinese biopharmaceutical companies and is the largest producer and supplier of vaccines and plasma-derived products in China. CNBG’s major business segments include human vaccines, blood products, medical aesthetics, veterinary vaccines, antibodies and diagnostics. Lanzhou is the sole producer of botulinum toxin in China. Heng Li® is the market leading botulinum toxin in the China market, with a market share of 75%, ranking No. 1 in the domestic market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005790/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
i2c Marks a Year of Momentum Driving Financial Institutions and Fintechs in the Race to Modernize21.10.2026 15:00:00 CEST | Press release
New client wins, expanded partnerships, and a wave of industry recognition reflect growing demand for i2c and its PowerOne platform i2c Inc., a global financial technology innovator, today recapped key milestones from the past year as financial institutions and fintechs raced to modernize their banking and payments technology. Behind that race is mounting pressure. New American Banker research in partnership with i2c found that 88% of financial institutions have accelerated their modernization timelines due to competition from digital-first banks, fintechs, and non-bank providers, with executives most often citing legacy processing architecture as the greatest barrier. Too many remain stuck choosing between legacy platforms with proven scale and modern platforms with agility. For more than 26 years, i2c has helped clients skip that trade-off entirely. i2c’s next-gen PowerOne unified banking and payments platform gives clients one global foundation to outperform competitors running on f
Civil Air Patrol Orders 21 New Cessna Aircraft to Strengthen Lifesaving and Community Missions21.10.2026 15:00:00 CEST | Press release
New Skyhawk, Skylane and Stationair aircraft will support CAP missions across the U.S., with deliveries anticipated in 2027 Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an order from Civil Air Patrol (CAP) for 21 additional Cessna piston aircraft that will support CAP's emergency response, training and community missions across the U.S. Deliveries are expected to be completed in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021955281/en/ Maj. Gen. Regena Aye and Brig. Gen. R. Jason Bailey of the Civil Air Patrol tour Cessna piston assembly at Textron Aviation’s facility in Independence, Kansas The order includes seven Cessna Skyhawk 172 aircraft, 11 Cessna Skylane 182 aircraft, two Cessna Turbo Skylane T182T aircraft and one Cessna Turbo Stationair HD 206 aircraft. CAP is the world's largest operator of Cessna aircraft. “These Cessna aircraft help ensure our members are ready when comm
Klarna Launches Consumer FX: Shop From Klarna Merchants Worldwide, Regardless of Currency21.10.2026 14:47:00 CEST | Press release
Klarna Group Plc (NYSE: KLAR), the everyday finance network, today launched Consumer FX, which allows shoppers to buy from any participating Klarna merchant in the world and pay in their own currency, with no exchange fee. The price and rate are shown upfront and stay visible in the Klarna app after purchase, so there are no surprises on the statement. The new launch means any Klarna connected merchant can sell to Klarna’s 120 million consumers in 26 countries with no new integration, and no need for a local entity of foreign bank account. Klarna also handles FX disclosure, consent and compliance. Early results show merchants gain a 5% lift in conversion and 6% in sales due to the expanded reach. The launch comes as cross-border payments are growing globally. DHL reports that 70% of 2026 shoppers buy internationally, up 10% from 2025, and 45% buy across borders more than once a month.1 “Increasingly, shoppers aren’t thinking in borders,” says David Sykes, Chief Commercial Officer, Klar
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21.10.2026 14:35:00 CEST | Press release
Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive and continuously available to people living with rare tumorsCollaboration brings together clinical and pharmaceutical expertise, digital health product development, and enterprise AI servicesMerck aims to bring the model to patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously ava
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom